The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.

IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the FDA regarding the development of CannQuit-N for tobacco smoking cessation and relapse control.

The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.

Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.

The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.